FDA Hatch/Waxman “Moot Court” To Examine Brand/Generic Legal Positions
FDA's chief counsel will host a "moot court" briefing on the brand and generic industry's arguments about the agency's interpretation of the Hatch/Waxman Act
FDA's chief counsel will host a "moot court" briefing on the brand and generic industry's arguments about the agency's interpretation of the Hatch/Waxman Act